HIPAA, GDPR, PIPEDA & PHIPA
Overlap and Differences for AI Startups
Healthcare AI startups often begin by building for a single market—only to discover that expanding into new regions requires significant privacy and compliance adjustments. While laws like HIPAA (U.S.), GDPR (EU), PIPEDA (Canada), and PHIPA (Ontario) share common goals, their definitions, requirements, and enforcement mechanisms differ in ways that can reshape your data architecture, consent processes, and vendor relationships.
For early-stage teams, understanding these similarities and differences before expansion can save time, reduce legal risk, and avoid costly product rework.
Updated: April 18, 2026
Why This Matters for Startups
Cross-border data challenges – Moving or processing data across jurisdictions triggers different obligations, especially under GDPR’s data transfer rules and PHIPA’s requirements for safeguards and accountability in cross-border data processing. Non-compliance can block partnerships or customer onboarding in target markets.
Conflicting consent standards – HIPAA’s authorization rules, GDPR’s explicit consent requirements, and PIPEDA/PHIPA’s consent models differ in formality, scope, and revocation rights. A consent form valid in one jurisdiction may be invalid in another.
Varying definitions of personal health data – What counts as protected health information under HIPAA may have a broader or narrower definition under GDPR, PIPEDA, or PHIPA. Startups that assume one standard applies globally risk under-protecting data in stricter jurisdictions.
Key Areas of Overlap
While each law has unique features, they share several core principles:
Purpose limitation – Data must be collected for a specific, lawful purpose and not used beyond that scope without new consent or legal basis.
Data minimization – Collect only the data necessary for the intended purpose.
Security safeguards – Implement administrative, technical, and physical measures to protect personal health data.
Individual rights – Patients or data subjects have rights to access, correct, and request deletion of their information (with some differences in scope).
Accountability – Organizations are responsible for demonstrating compliance through policies, training, and documentation.
Privacy Law Comparison Table
| Feature / Requirement | HIPAA (U.S.) | GDPR (EU) | PIPEDA (Canada) | PHIPA (Ontario) |
|---|---|---|---|---|
| Scope | Applies to covered entities and business associates handling PHI in U.S. healthcare. | Aapplies to organizations established in the EU, and to organizations outside the EU when they offer goods or services to individuals in the EU or monitor their behavior there. | Applies to most private-sector organizations in Canada, unless a province has its own law. | Applies to health information custodians and their agents in Ontario. |
| Type of Data Covered | Protected Health Information (PHI). | Personal data, with health data as a special category. | Personal information, including health data. | Personal health information (PHI) specific to Ontario. |
| Consent Standard | Often allows PHI use for treatment, payment, and operations without explicit consent; requires authorization for other uses. | Requires explicit consent for processing health data unless another lawful basis applies. | Express or implied consent depending on sensitivity; health data usually requires express consent. | Implied consent allowed within circle of care; express consent required for other disclosures. |
| Data Residency / Transfers | No residency requirement; must safeguard PHI wherever stored. | Transfers outside EEA require adequacy decisions or safeguards. | Allows cross-border transfers with accountability for protection. | Practical implications for where health data can be stored, particularly in public systems. |
| Key Individual Rights | Access, amendments, and accounting of disclosures. | Access, rectification, erasure, data portability, restriction, objection. | Access and correction rights. | Access and correction rights, with some limitations. |
| Enforcement & Penalties | Civil and criminal penalties; fines may reach up to about $1.5 million per violation category in severe cases | Administrative fines up to €20M or 4% of global turnover. | Federal enforcement; fines vary by case, generally lower than GDPR. | Provincial enforcement; penalties up to CAD $200,000 per individual offense. |
Key Differences Startups Should Know
1. Scope of Application
- HIPAA applies to covered entities and business associates in the U.S. healthcare system.
- GDPR applies to any organization processing personal data of EU residents, regardless of where the organization is based.
- PIPEDA applies to most private-sector organizations in Canada, with some provincial exceptions.
- PHIPA applies specifically to Ontario health information custodians and their agents.
2. Consent Requirements
- HIPAA often permits PHI use for treatment, payment, and healthcare operations without explicit consent, but requires authorization for other uses.
- GDPR typically requires explicit consent for processing health data unless another legal basis applies (e.g., public interest, vital interests).
- PIPEDA allows implied or express consent depending on context; sensitive health data typically requires express consent.
- PHIPA generally permits implied consent within the circle of care but requires express consent for other disclosures.
3. Data Residency and Transfer Rules
- GDPR restricts personal data transfers outside the EEA unless adequate safeguards are in place.
- PHIPA can impose constraints or expectations on the storage and handling of health information, especially in public health systems.
- PIPEDA allows cross-border transfers but requires organizations to maintain accountability and comparable protections.
- HIPAA has no explicit residency requirement but still mandates safeguarding PHI wherever stored.
Practical Steps for Startups
1. Map your data flows across jurisdictions
Identify where your data is collected, processed, stored, and transferred. Flag steps that involve multiple jurisdictions to determine applicable laws.
2. Create multi-jurisdiction consent templates
Build consent language that meets or exceeds the strictest applicable standard so it remains valid across all target markets.
3. Align vendor contracts with all applicable laws
Vendors handling health data should meet requirements for every jurisdiction you operate in, not just your home market.
4. Document your legal basis for processing
For each market, record whether you rely on consent, contractual necessity, public interest, or another lawful basis.
Key Takeaways
- Expanding internationally means layering multiple privacy regimes, not replacing one with another.
- Designing compliance for the strictest applicable standard early can reduce friction when entering new markets.
- Documentation of consent, processing activities, and vendor compliance is critical for both audits and investor due diligence.
Relevant Resources
- HHS HIPAA Privacy Rule Summary – Overview of HIPAA’s privacy requirements: https://www.hhs.gov/hipaa/for-professionals/privacy/index.html
- European Data Protection Board – GDPR Guidance – Official EU interpretations of GDPR obligations:https://edpb.europa.eu/our-work-tools/our-documents/guidelines-recommendations-best-practices_en
- Office of the Privacy Commissioner of Canada – PIPEDA Overview – Summary of Canada’s federal privacy law:https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/
- Information and Privacy Commissioner of Ontario – PHIPA Guide – PHIPA requirements for Ontario health custodians:https://www.ipc.on.ca/privacy/health-privacy/
EU AI Act in General
The EU Artificial Intelligence Act (AI Act) was first proposed in April 2021 and entered into force on 1 August 2024. Obligations apply in phases: 2 February 2025 for bans on prohibited AI systems, 2 August 2025 for general-purpose AI obligations, and 2 August 2026 for most high-risk AI obligations. It is the world’s first comprehensive legal framework specifically regulating artificial intelligence, aiming to ensure that AI systems placed on the EU market are safe, respect fundamental rights, and align with European values.
Much like the General Data Protection Regulation (GDPR), the AI Act is expected to exert a global influence — often referred to as the “Brussels Effect.” Organizations worldwide are likely to adapt their AI practices to EU requirements in order to maintain access to the European market. This is particularly significant for healthcare, where AI systems directly affect patient safety and data protection.
Scope of Application
The AI Act applies to:
- Providers (developers, manufacturers) of AI systems placing products on the EU market.
- Users of AI systems within the EU, including healthcare institutions.
- Organizations outside the EU whose AI systems are either used within the EU market or affect the rights and freedoms of EU residents.
How it Applies to AI in Healthcare
Healthcare AI systems are frequently categorized as ‘high-risk’ under the AI Act, particularly when used for diagnostic, treatment, or decision-support purposes in clinical settings. Given their direct impact on health and safety, these systems must comply with the Act’s legal requirements. Non-compliance may lead to significant fines under Article 99 of the AI Act. The most serious infringements, such as the use of prohibited AI systems, can result in administrative fines of up to €35 million or 7% of global annual turnover, whichever is higher.
The Four-Tier Risk Classification System
- Unacceptable Risk: AI systems banned outright. Examples include government social scoring and AI toys encouraging dangerous behavior. Most uses of real-time biometric surveillance in public spaces are prohibited, with narrow exceptions for law enforcement (such as locating missing persons or preventing terrorist threats).
- High Risk: AI used in sensitive domains, including healthcare and medical devices. Subject to strict requirements such as risk management, data governance, bias mitigation, human oversight, transparency standards, technical documentation, and conformity assessments.
- Limited Risk: AI systems like chatbots or emotion recognition tools. These require transparency obligations, such as informing users that they are interacting with AI.
- Minimal or No Risk: AI with little or no impact on rights or safety, such as spam filters or gaming AI. These face no additional obligations.
Key Obligations for High-Risk AI Systems
- Ensure eligible high-risk AI systems are registered in the official EU database before being placed on the EU market.
- Conduct continuous risk management and conformity assessments before deployment.
- Maintain detailed technical documentation for accountability.
- Ensure human-in-the-loop oversight in decision-making processes.
- Implement post-market monitoring and incident reporting procedures.
- Adopt robust data governance and bias prevention frameworks.
Impact on Innovation and Compliance
The AI Act is widely regarded as a leading global benchmark for responsible AI governance. Supporters argue it fosters trust, aligns with the EU Charter of Fundamental Rights, and enhances patient safety in healthcare. Critics caution that compliance costs may challenge startups and SMEs, potentially slowing innovation. To mitigate this, the EU will provide regulatory sandboxes and technical guidance, allowing organizations to test AI systems under supervision while working toward compliance.
The Road Ahead
The AI Act is the beginning of a broader European regulatory framework for AI. Additional measures are under discussion, particularly regarding:
- Foundation Models: Oversight for large-scale general-purpose models (e.g., GPT-based systems).
- General-Purpose AI (GPAI): Clarified obligations for generative and adaptive AI systems.
- Adaptive AI Systems: The Act includes requirements to ensure AI systems that evolve after deployment continue to comply with obligations and remain safe.
Enforcement is phased:
-
2 February 2025: Bans on prohibited AI systems
-
2 August 2025: Obligations for general-purpose AI
-
2 August 2026: Full enforcement of high-risk AI obligations
Relevant and Overlapping Laws
Compliance with the AI Act should be aligned with other frameworks to ensure comprehensive governance:
- GDPR: Ensures data protection and patient privacy in tandem with AI Act requirements.
- PHIPA (Ontario): Provincial privacy law for health data in Canada, relevant for cross-border alignment.
- ISO/IEC 27001: Information security management standards for enterprise-wide controls.
- ISO/IEC 42001: AI governance standard for managing AI lifecycles and risks.
- OECD AI Principles: Promote fairness, accountability, and transparency in AI systems.
- NIST AI RMF: U.S. framework for managing risks in trustworthy AI development.
References & Official Source
EU Artificial Intelligence Act (Regulation (EU) 2024/1689): https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng
AI Act — PDF of Official Journal version: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ%3AL_202401689
AI Act Explorer (summary + languages): https://artificialintelligenceact.eu/the-act/
High-Level Summary of the AI Act: https://artificialintelligenceact.eu/high-level-summary/
EU AI Act in General
The EU Artificial Intelligence Act (AI Act) was first proposed in April 2021 and entered into force on 1 August 2024. Obligations apply in phases: 2 February 2025 for bans on prohibited AI systems, 2 August 2025 for general-purpose AI obligations, and 2 August 2026 for most high-risk AI obligations. It is the world’s first comprehensive legal framework specifically regulating artificial intelligence, aiming to ensure that AI systems placed on the EU market are safe, respect fundamental rights, and align with European values.
Much like the General Data Protection Regulation (GDPR), the AI Act is expected to exert a global influence — often referred to as the “Brussels Effect.” Organizations worldwide are likely to adapt their AI practices to EU requirements in order to maintain access to the European market. This is particularly significant for healthcare, where AI systems directly affect patient safety and data protection.
Scope of Application
The AI Act applies to:
- Providers (developers, manufacturers) of AI systems placing products on the EU market.
- Users of AI systems within the EU, including healthcare institutions.
- Organizations outside the EU whose AI systems are either used within the EU market or affect the rights and freedoms of EU residents.
How it Applies to AI in Healthcare
Healthcare AI systems are frequently categorized as ‘high-risk’ under the AI Act, particularly when used for diagnostic, treatment, or decision-support purposes in clinical settings. Given their direct impact on health and safety, these systems must comply with the Act’s legal requirements. Non-compliance may lead to significant fines under Article 99 of the AI Act. The most serious infringements, such as the use of prohibited AI systems, can result in administrative fines of up to €35 million or 7% of global annual turnover, whichever is higher.
The Four-Tier Risk Classification System
- Unacceptable Risk: AI systems banned outright. Examples include government social scoring and AI toys encouraging dangerous behavior. Most uses of real-time biometric surveillance in public spaces are prohibited, with narrow exceptions for law enforcement (such as locating missing persons or preventing terrorist threats).
- High Risk: AI used in sensitive domains, including healthcare and medical devices. Subject to strict requirements such as risk management, data governance, bias mitigation, human oversight, transparency standards, technical documentation, and conformity assessments.
- Limited Risk: AI systems like chatbots or emotion recognition tools. These require transparency obligations, such as informing users that they are interacting with AI.
- Minimal or No Risk: AI with little or no impact on rights or safety, such as spam filters or gaming AI. These face no additional obligations.
Key Obligations for High-Risk AI Systems
- Ensure eligible high-risk AI systems are registered in the official EU database before being placed on the EU market.
- Conduct continuous risk management and conformity assessments before deployment.
- Maintain detailed technical documentation for accountability.
- Ensure human-in-the-loop oversight in decision-making processes.
- Implement post-market monitoring and incident reporting procedures.
- Adopt robust data governance and bias prevention frameworks.
Impact on Innovation and Compliance
The AI Act is widely regarded as a leading global benchmark for responsible AI governance. Supporters argue it fosters trust, aligns with the EU Charter of Fundamental Rights, and enhances patient safety in healthcare. Critics caution that compliance costs may challenge startups and SMEs, potentially slowing innovation. To mitigate this, the EU will provide regulatory sandboxes and technical guidance, allowing organizations to test AI systems under supervision while working toward compliance.
The Road Ahead
The AI Act is the beginning of a broader European regulatory framework for AI. Additional measures are under discussion, particularly regarding:
- Foundation Models: Oversight for large-scale general-purpose models (e.g., GPT-based systems).
- General-Purpose AI (GPAI): Clarified obligations for generative and adaptive AI systems.
- Adaptive AI Systems: The Act includes requirements to ensure AI systems that evolve after deployment continue to comply with obligations and remain safe.
Enforcement is phased:
-
2 February 2025: Bans on prohibited AI systems
-
2 August 2025: Obligations for general-purpose AI
-
2 August 2026: Full enforcement of high-risk AI obligations
Relevant and Overlapping Laws
Compliance with the AI Act should be aligned with other frameworks to ensure comprehensive governance:
- GDPR: Ensures data protection and patient privacy in tandem with AI Act requirements.
- PHIPA (Ontario): Provincial privacy law for health data in Canada, relevant for cross-border alignment.
- ISO/IEC 27001: Information security management standards for enterprise-wide controls.
- ISO/IEC 42001: AI governance standard for managing AI lifecycles and risks.
- OECD AI Principles: Promote fairness, accountability, and transparency in AI systems.
- NIST AI RMF: U.S. framework for managing risks in trustworthy AI development.
References & Official Source
EU Artificial Intelligence Act (Regulation (EU) 2024/1689): https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng
AI Act — PDF of Official Journal version: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ%3AL_202401689
AI Act Explorer (summary + languages): https://artificialintelligenceact.eu/the-act/
High-Level Summary of the AI Act: https://artificialintelligenceact.eu/high-level-summary/